Cancer stem-like cells act via distinct signaling pathways in promoting late stages of malignant progression

Cancer Research

Volumn 76, Issue 5, 2016, Pages 1245-1259

  Da Silva Diz, Victoria ^a   Simon Extremera, Pilar ^a   Bernat Peguera, Adria ^a   De Sostoa, Jana ^a   Urpí, Maria ^a   Penín, Rosa M ^b   Sidelnikova, Diana Perez ^b   Bermejo, Oriol ^b   Vinals, Joan Maria ^b   Rodolosse, Annie ^c   Gonzalez Suarez, Eva ^a   Moruno, Antonio Gomez ^a   Pujana, Miguel Angel ^d   Esteller, Manel ^a,e,f   Villanueva, Alberto ^d   Vinals, Francesc ^d,e   Munoz, Purificacion ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER STEM CELL; CD34 SELECTION; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; UPREGULATION; ANIMAL; CANCER STAGING; DISEASE COURSE; PATHOLOGY; PHYSIOLOGY; SECONDARY; SKIN TUMOR;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINEAGE; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; MICE; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PLATELET-DERIVED GROWTH FACTOR; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84961761090     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1631     Document Type: Article

References (50)

1. Cherpelis BS, Marcusen C, Lang PG Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg 2002; 28:268-73.
2. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992; 54:63-128.
3. Coussens LM, Hanahan D, Arbeit JM Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 1996; 149:1899-917.
4. Franco R, Nicoletti G, Lombardi A., Di Domenico M, Botti G, Zito Marino F, et al. Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs. Expert Opin Biol Ther 2013; 13:51-66.
5. Visvader JE. Cells of origin in cancer. Nature 2011; 469:314-22.
6. Nguyen LV, Vanner R, Dirks P., Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012; 12:133-43.
7. Chen J, Li Y, Yu T.S., McKay RM, Burns DK, Kernie SG, et al A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488:522-6.
8. Pattabiraman DR, Weinberg RA Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov 2014; 13:497-512.
9. Mani SA, Guo W, Liao M.J., Eaton EN, Ayyanan A, Zhou AY, et al The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15.
10. Thiery JP, Acloque H, Huang R.Y., Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-90.
11. Malanchi I, Peinado H, Kassen D., Hussenet T, Metzger D, Chambon P, et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008; 452:650-3.
12. Lapouge G, Beck B, Nassar D., Dubois C, Dekoninck S, Blanpain C. Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness. EMBO J 2012; 31:4563-75.
13. Siegle JM, Basin A, Sastre-Perona A, Yonekubo Y., Brown J, Sennett R, et al SOX2 is a cancer-specific regulator of tumour initiating potential in cutaneous squamous cell carcinoma. Nat Commun 2014; 5:4511.
14. Boumahdi S, Driessens G, Lapouge G., Rorive S, Nassar D, Le Mercier M, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 2014; 511:246-50.
15. Beck B, Driessens G, Goossens S., Youssef KK, Kuchnio A, Caauwe A, et al A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011; 478:399-403.
16. Schober M, Fuchs E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci USA 2011; 108:10544-9.
17. Arbeit JM, Munger K, Howley P.M., Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 1994; 68:4358-68.
18. Blanco R, Munoz P, Flores J.M., Klatt P., Blasco MA. Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev 2007; 21:206-20.
19. da Silva-Diz V, Sole-Sanchez S, Valdes-Gutierrez A, Urpí M, Riba-Artes D, Penin RM, et al. Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis. Oncogene 2013; 32:3732-43.
20. Munoz P, Blanco R, Flores J.M., Blasco MA. XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nat Genet 2005; 37:1063-71.
21. Gonzalez-Roca E., Garcia-Albeniz X, Rodriguez-Mulero S, Gomis RR, Kornacker K, Auer H. Accurate expression profiling of very small cell populations. PLoS One 2010; 5:e14418.
22. Wong CE, Yu JS, Quigley D.A., To MD, Jen KY, Huang PY, et al Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. Genes Dev 2013; 27:670-82.
23. Quintanilla M, Brown K, Ramsden M., Balmain A. Carcinogen-specific mutation and amplification of Haras during mouse skin carcinogenesis. Nature 1986; 322:78-80.
24. Nassar D, Latil M, Boeckx B., Lambrechts D, Blanpain C. Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat Med 2015; 21:946-54.
25. Holderfield M, Lorenzana E, Weisburd B., Lomovasky L, Boussemart L, Lacroix L., et al. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res 2014; 74:2238-45.
26. Hynes NE, Lane HA ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-54.
27. Jechlinger M, Sommer A, Moriggl R., Seither P, Kraut N, Capodiecci P., et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 2006; 116:1561-70.
28. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10:116-29.
29. Fuerer C, Nusse R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS One 2010; 5:e9370.
30. Hansen LA, Woodson RL II, Holbus S, Strain K, Lo Y.C., Yuspa SH. The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. Cancer Res 2000; 60:3328-32.
31. Sibilia M, Fleischmann A, Behrens A., Stingl L, Carroll J, Watt F.M., et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 2000; 102:211-20.
32. Ponten F, Ren Z, Nister M., Westermark B, Ponten J. Epithelial-stromal interactions in basal cell cancer: the PDGF system. J Invest Dermatol 1994; 102:304-9.
33. Hwang RF, Yokoi K, Bucana C.D., Tsan R., Killion JJ, Evans DB, et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003; 9:6534-44.
34. Ruan J, Luo M, Wang C., Fan L, Yang SN, Cardenas M, et al Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 2013; 121: 5192-202.
35. Yang J, Meyer M, Muller A.K., Böhm F, Grose R., Dauwalder T, et al. Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis. J Cell Biol 2010; 188: 935-52.
36. Mohammadi M, Froum S, Hamby J.M., Schroeder MC, Panek RL, Lu GH, et al Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998; 17:5896-904.
37. Biddle A, Liang X, Gammon L., Fazil B, Harper LJ, Emich H, et al Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011; 71:5317-26.
38. Geng S, Guo Y, Wang Q., Li L, Wang J. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelialmesenchymal transition in squamous cell carcinoma. Arch Dermatol Res 2012; 305:35-47.
39. Wilkerson MD, Yin X, Hoadley K.A., Liu Y., Hayward MC, Cabanski CR, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 2010; 16:4864-75.
40. Network CGAR. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519-25.
41. Rickman DS, Millon R, DeReynies A, Thomas E, Wasylyk C, Muller D, et al. Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene 2008; 27:6607-22.
42. White RA, Neiman JM, Reddi A, Han G., Birlea S, Mitra D, et al Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. J Clin Invest 2013; 123:4390-404.
43. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O., Werb Z, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-97.
44. Jacobson RH. Immunodeficiency models in characterization of immune responses to parasites-an overview. Vet Parasitol 1982; 10:141-54.
45. Zhang L, Ge Y, Fuchs E. miR-125b can enhance skin tumor initiation and promote malignant progression by repressing differentiation and prolonging cell survival. Genes Dev 2014; 28:2532-46.
46. Lamont FR, Tomlinson DC, Cooper P.A., Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011; 104: 75-82.
47. Singh A, Greninger P, Rhodes D., Koopman L, Violette S, Bardeesy N., et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009; 15:489-500.
48. Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, et al. Protein kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 2013; 24:347-64.
49. Zhu DY, Guo QS, Li Y.L., Cui B., Guo J, Liu JX, et al Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression. World J Gastroenterol 2014; 20:18306-15.
50. Kreso A, Dick JE Evolution of the cancer stem cell model. Cell Stem Cell 2014; 14:275-91.